BSEClinitech Laboratory LtdMinimalNeutral
Announced Tue, 7 Jul · 17:53 IST

RTA confirms Reg 74(5) compliance; all shares held in demat form

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Clinitech Laboratory has submitted a routine quarterly disclosure under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The company's Registrar and Transfer Agent, Bigshare Services, confirmed that the regulation is not applicable since all company shares are held in dematerialised form. No rematerialisation requests were received from any shareholder during the quarter. Filed by Chairman and Managing Director Jagdish Umakant Nayak.

Likely market impact

No material impact; purely procedural compliance filing with no effect on business or shareholders.